CAS NO: | 1715025-34-5 |
包装 | 价格(元) |
5mg | 电议 |
10mg | 电议 |
25mg | 电议 |
50mg | 电议 |
100mg | 电议 |
生物活性 | Rineterkib hydrochloride (compound B) is an orally availableERK1andERK2inhibitor in the treatment of a proliferative disease characterized by activating mutations in the MAPK pathway. The activity is particularly related to the treatment of KRAS-mutant NSCLC, BRAF-mutant NSCLC, KRAS-mutant pancreaticcancer, KRAS-mutant colorectalcancer(CRC) and KRAS-mutant ovariancancer. Rineterkib hydrochloride can also inhibitRAF[1][2]. | ||||||||
体内研究 (In Vivo) | ERK-IN-1 (compound B) (50, 75 mg/kg, p.o., qd/q2d, 27 days) treatment significantly reduces the tumor volume in the Calu-6 human NSCLC subcutaneous tumor xenograft model in mice[1].
| ||||||||
Clinical Trial | |||||||||
性状 | Solid | ||||||||
Formula | C26H28BrClF3N5O2 | ||||||||
CAS 号 | 1715025-34-5 | ||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||
储存方式 | 4°C, sealed storage, away from moisture and light *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light) | ||||||||
溶解性数据 | In Vitro: DMSO : 220 mg/mL(Need ultrasonic) In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
|